THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED
STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
OTTAWA, March 12, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the
“Company”), a life sciences innovation company with a series of patent protected products that support and
optimize human and animal health, announces that it has received approval by the TSX Venture Exchange to extend the expiry date of
outstanding warrants exercisable to purchase 1,163,738 common shares at $1.00 per share. Such warrants were issued by Avivagen on
December 16, 2014 by way of a private placement and previously had an expiry date of December 16, 2017, which was later extended to
June 30, 2018. The new expiry date is October 1, 2018. The Company has also received approval to extend the expiry date of a
second tranche of outstanding warrants exercisable to purchase 2,774,991 common shares at $0.90 per share. These warrants were
issued by Avivagen on June 1, 2016 by way of a private placement and previously had an expiry date of June 1, 2018. The new expiry
date is October 1, 2018. All other terms and conditions of the warrants remain unchanged. The Company’s intention to
seek extension of these warrants was previously announced on February 13, 2018.
About Avivagen
Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in
Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island.
For more information, visit www.avivagen.com.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain
fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™
Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock
feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all
in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock
have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
About Vivamune™ Health Chews (Vivamune)
Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a
newly-discovered, novel immune-supporting active ingredient: OxC-beta™ compound, Vivamune targets joints, skin and digestive health
all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit
www.vivamunehealth.com.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of
management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”,
“could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, "may”, “plan”, “possibly”, “potentially”, “pursue”,
“seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements about the potential for Avivagen Inc.’s products
to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are forward- looking statements. These
forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ
materially from current expectations.. Except as required by law, Avivagen assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from those reflected in the forward-looking
statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony
Chairman & Interim CEO
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Copyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
![Primary Logo](https://resource.globenewswire.com/Resource/Download/36d34616-cf91-499e-8119-1b4c5fbee0ab?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2NDAjNzE4OTQxNw==)